Updated SOFTWARE Act: Still Too Ambiguous For Industry?
This article was originally published in The Gray Sheet
Executive Summary
While some industry experts say the updated version of the SOFTWARE Act strikes a tenable balance between industry's need for certainty and FDA's need to ensure patient safety, others argue it does not go far enough to explicitly state what kinds of health IT software the agency will not regulate.
You may also be interested in...
Industry: New SOFTWARE Act Provides Certainty
Rep. Blackburn’s SOFTWARE Act has changed substantially since it was first introduced and is being praised by device manufacturers for providing much needed clarity on how far FDA can go to regulate Medical and Health software.
Active Months Ahead For mHealth Regulatory Policymaking
Multiple guidances, frameworks and legislative activity on mHealth are expected to surface this fall and could have major implications on how the emerging industry is regulated.
Sandoz Stands Alone As It Completes Novartis Spinoff
Sandoz has heralded a “new era as a standalone global leader and European champion in generic and biosimilar medicines” after completing its long journey towards independence by separating from former parent company Novartis.